Exclusive Interview

MDS' sites "perfectly dovetail" with Ricerca's capacity; VP

By Nick Taylor

- Last updated on GMT

Related tags: President of the united states

The capabilities of the MDS Pharma Services' sites Ricerca is set to acquire "perfectly dovetail" with its existing capacity, according to a company vice president.

Speaking to Outsourcing-Pharma at Informex 2010, Mark Crane, vice president, business development and marketing at Ricerca, explained that services proivided by the MDS' sites take clients up to the developmental stage that Ricerca traditionally began working with companies.

Acquiring the MDS' sites increases Ricerca's headcount from 270 to over 800 and expands the company into new geographies. Despite this, Crane believes that integration will be relatively straightforward because of the lack of overlap between Ricerca's existing capacity and the acquired sites.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more


View more